Voloridge Investment Management
RARE icon

Voloridge Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Voloridge Investment Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.5M Sell
1,241,556
-185,278
-13% -$4.6M 0.18% 187
2026
Q1 		$29.9M Buy
1,426,834
+783,478
+122% +$17.6M 0.12% 247
2025
Q4 		$14.8M Buy
643,356
+160,774
+33% +$5.29M 0.05% 458
2025
Q3 		$14.5M Buy
+482,582
New +$14.5M 0.05% 437
2024
Q4 		– Sell
-52,266
Closed -$2.9M – 1337
2024
Q3 		$2.9M Buy
+52,266
New +$2.66M 0.01% 879
2023
Q3 		– Sell
-19,027
Closed -$878K – 1566
2023
Q2 		$878K Sell
19,027
-101,447
-84% -$4.71M ﹤0.01% 1146
2023
Q1 		$4.83M Buy
120,474
+34,640
+40% +$1.49M 0.02% 679
2022
Q4 		$3.98M Buy
85,834
+68,139
+385% +$2.68M 0.02% 735
2022
Q3 		$733K Buy
+17,695
New +$909K ﹤0.01% 1212
2022
Q2 		– Sell
-26,295
Closed -$1.91M – 1604
2022
Q1 		$1.91M Sell
26,295
-21,521
-45% -$1.5M 0.01% 967
2021
Q4 		$4.02M Buy
47,816
+36,062
+307% +$2.93M 0.02% 796
2021
Q3 		$1.06M Sell
11,754
-16,702
-59% -$1.51M 0.01% 1262
2021
Q2 		$2.71M Buy
28,456
+23,854
+518% +$2.49M 0.02% 872
2021
Q1 		$524K Sell
4,602
-6,983
-60% -$951K ﹤0.01% 1170
2020
Q4 		$1.6M Buy
11,585
+904
+8% +$107K 0.01% 814
2020
Q3 		$878K Buy
+10,681
New +$885K 0.01% 976
2020
Q1 		– Sell
-21,635
Closed -$924K – 1335
2019
Q4 		$924K Buy
+21,635
New +$893K 0.02% 671
2018
Q3 		– Sell
-18,470
Closed -$1.42M – 437
2018
Q2 		$1.42M Buy
+18,470
New +$1.19M 0.04% 294

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Voloridge Investment Management's RARE Position: Q2 2026 in Review

Voloridge Investment Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 13% in Q2 2026, selling an estimated $4.6M and leaving 1,241,556 shares worth $41.5M. The position accounts for 0.18% of the portfolio, ranked #187.

Voloridge Investment Management first reported a position in RARE in Q2 2018 and has held it in 18 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Voloridge Investment Management held 1,241,556 shares of Ultragenyx Pharmaceutical worth $41.5M as of Q2 2026.
  • Voloridge Investment Management sold 185,278 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $4.6M.
  • Ultragenyx Pharmaceutical made up 0.18% of Voloridge Investment Management's portfolio in Q2 2026, its #187 holding.
  • Voloridge Investment Management first reported a position in Ultragenyx Pharmaceutical in Q2 2018 and has held it in 18 quarters since.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.